Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands.

Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Part of Zoetis, Inc., Zoetis Services LLC is a company headquartered in Florham Park, NJ, that discovers, develops, manufactures and sells animal health medicines and vaccines.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

D. E. Shaw Research ("DESRES") is engaged in scientific research and technological development in the field of computational biochemistry, including - The design of novel algorithms and machine architectures for high-speed molecular dynamics (MD) simulations of proteins and other biological macromolecules. In particular, they have designed and constructed a specialized supercomputer called Anton, which executes such simulations orders of magnitude faster than was previously possible, along with a number of software tools and techniques that facilitate their execution and analysis. - The use of long MD simulations to study the structural changes underlying biological phenomena that occur on time scales far in excess of those previously accessible to computational study, with the ultimate aim of significantly advancing the process of drug discovery. They have been investigating, for example, the mechanisms of certain cellular receptors, transport proteins, and enzymes relevant to the understanding and potential treatment of cancer, diabetes, and other diseases. Their research team includes computational chemists and biologists, computer scientists and applied mathematicians, and computer architects and engineers, all working collaboratively under the leadership of its chief scientist, David Shaw.

Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.

PANAGENE Inc. engages in the molecular diagnostics business. It develops, manufactures and sells peptide nucleic acid (PNA) genetic diagnostic chips. The firm operates through the PNA Materials and Diagnostic Product business divisions. Its products are marketed as PANAMutyper, PNAClamp, PANArray, PANA qPCR, PNA Oligo and Monomer. The company was founded on April 16, 2001 and is headquartered in Daejeon, South Korea.

CTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in a first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P.

YM BioSciences Australia Pty Ltd., a subsidiary of Gilead Sciences, Inc., is a company headquartered in Melbourne, Australia, that develops cancer treatment pharmaceuticals.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Anhui Jiren Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of modern Chinese medicine. It offers Chinese patent medicine, Chinese herbal medicine, and Chinese medicine formula granules. The company was founded on April 19, 2001 and is headquartered in Bozhou, China.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Konkuk University Industry-Academic Cooperation Foundation increases the competitiveness of industries by linking company and university.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.